Cargando…

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial

BACKGROUND: Preclinical and clinical studies suggest that β(3)‐adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This proof‐of‐concept study evaluated the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Brian E., King, Jennifer, Shortino, Denise, Schaumburg, Chris, Haag‐Molkenteller, Cornelia, Chey, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078113/
https://www.ncbi.nlm.nih.gov/pubmed/35975404
http://dx.doi.org/10.1111/nmo.14448